A site where you can find recommended contractors for non-clinical testing｜effical " Non-Clinical CROs and Agencies " Aragen Life Sciences Ltd.

Aragen Life Sciences Ltd.

Table of Contents

This article introduces Aragen Life Sciences Ltd., an Indian biopharmaceutical company. The company is a CRO (contract research organization) that provides in-house R&D services, including non-clinical trials, and its core business is CRDMO services, which provide comprehensive support from the concept stage to commercialization. The following is a survey and summary of the characteristics of the company's contract non-clinical testing services.

Aragen Life Sciences Ltd.'s Contract Nonclinical Trial Services Feature

Possesses research facilities with GLP certification

Aragen Life Sciences Ltd. provides in-house research and development services, including non-clinical trials. The company's core business is CRDMO services, which provide total support for new drugs from the idea stage to commercialization, and it has business relationships with a large number of companies. To support this business, Aragen Life Sciences Ltd. has a research facility in Pune, India. This facility is GLP (Good Laboratory Practices) and AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care) certified, and is also in line with OECD (Organization for Economic Cooperation and Development) standards.

Offering a wide range of services

Aragen Life Sciences Ltd. offers a wide range of services for both Small Molecules and Large Molecules (Biologics). Non-clinical trials are mainly positioned as "safety evaluation" in the early stages of drug discovery. In particular, safety evaluation is listed as a core service along with integrated drug discovery, chemistry, and biology in the small molecule drug discovery services. This is indicative of the company's desire to incorporate non-clinical testing from the earliest stages of the drug discovery process, leading to more efficient development.

Serving a diverse range of industries.

The company's non-clinical testing services are not limited to the pharmaceutical and biotech industries, but also serve the industrial chemical and agrochemical industries. The company's ability to serve such a diverse range of industries is due to its robust technical foundation and its expertise and flexibility in evaluating the safety of not only pharmaceuticals, but also a wide variety of chemicals and biotechnology products.

3 Specialized Pre-clinical CROs for Advanced Drug Discovery

An example of Aragen Life Sciences Ltd.'s pathological model

The company offers a variety of pathological models, one example being a model to advance research on glioblastoma (glioblastoma / GBM). This model allows for the study of the disease and the validation of treatments by injecting human glioblastoma cells into the brain of a thymus-free nude mouse to create a tumor, thus enabling the study of the disease in conditions similar to those of human disease.

In addition, various other models of inflammation and pain are available, including a CFA-induced inflammatory pain model using rats.

Aragen Life Sciences Ltd. Non-clinical Case Studies

No specific case studies were available on the official website.

Aragen Life Sciences Ltd. Company Information

Aragen Life Sciences Ltd. has several offices in India as well as in the U.S., serving a variety of companies.

Address	28 A, IDA Nacharam Hyderabad 500 076, India
Tel	+91 40 6692 9999
Website	https://www.aragen.com

3 Recommended Contract Research Organizations for Non-Clinical Studies
— by Target goal and Expertise

In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D. In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening. Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.

Pharmacology (Efficacy) Studies
Replicate unknown pathological models and
Discovery to clinically oriented drug evaluation

SMC Laboratories, Inc.

Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/jp/)

SMC Laboratories, Inc. has established a disease models using patented mouse technologies. The company has established proprietary pathological models—particularly in liver disease and fibrosis—and continues to expand their approach across a wide range of models in cancer, inflammation, and metabolic diseases.
From exploratory research to clinically oriented efficacy evaluation, SMC offers customized study designs, dosing strategies, and evaluation analysis tailored to each project. Their collaborative approachallows researchers to discuss and refine study plans together with SMC’s expert scientists.
With flexible small-scale study options and strong technical support, SMC Laboratories, Inc. is an ideal partner for start-ups, biotech ventures, and academic institutions alike.

Consult study design and disease model development
with SMC Laboratories, Inc.

Consult SMC Laboratories
Call us

Safety Studies
Comprehensive Safety Evaluation for FIH Applications

Labcorp Holdings Inc.
(Labcorp Drug Development)

Reference: Labcorp Holdings Inc. official website (https://jp.labcorp.com/)

Labcorp Holdings Inc. provides a fully integrated GLP testing system aligned with international regulatory standards, including FDA, EMA, and PMDA requirements. All studies are conducted under ICH-compliant quality assurance, making it ready for data submission.
The company has extensive expertise in long-term toxicity studies such as Segment I–III reproductive and carcinogenicity studies, as well as 2-year chronic toxicity assessments.
Labcorp Holdings Inc.’s comprehensive approach enables sponsors to efficiently outsource the entire preclinical package from toxicology, toxicokinetic (TK), and safety pharmacology study design to execution. This accelerates a path to First-in-Human (FIH) trials. For most of the global drug developers, this all-in-one service structure minimizes cost, risk, and expedite the time before advancing to clinical phase.

Consult Labcorp Holdings Inc.
Discuss GLP/ICH-compliant study design for your FIH submission.

To labcorp.
Call us

Pharmacokinetic (PK/PD) Studies
High-Precision Bioanalysis for Clinically Predictive PK/PD Evaluation

PhoenixBio Co., Ltd.

Source: PhoenixBio Co., Ltd. Official Website (https://phoenixbio.co.jp/)

PhoenixBio Co., Ltd.offers pharmacokinetic and hepatic metabolism studies using their proprietary PXB-mouse®, a humanized-liver chimeric mouse model. This platform enables the acquisition of data with high clinical correlation in ADME, drug–to-drug interaction studies, bridging the gap between preclinical and clinical stages.
With advanced LC-MS/MS-based bioanalysis, PhoenixBio Co., Ltd. provides aseamless workflow from plasma concentration measurement and metabolite identification to quantitative validation.
The company offersan integrated evaluation analysiscovering pharmacokinetics, hepatotoxicity, and safety with flexibility to accommodate complex modalities such as oligonucleotide and middle-molecule therapeutics. For compounds where hepatic metabolism is a development bottleneck—or where quantitative, reproducible exposure data are critical—PhoenixBio Co., Ltd. delivers unmatched analytical precision and consistency.

Consult Phoenix Bio for PK/PD analysis with a clinical focus

Phoenix Bio.
Call us